Ann: US FDA Type C Meeting for ATL1102 in DMD, page-19

Wise,

This is material - they have just told the market that all "clinical" factors are good i.e. no safety concerns re dosage that were hanging around from legacy MS trials.

The "non clinical" aspects may be related to regulatory / combination therapy partners / recruitment criteria ....ambulant, non-ambulant...or both?

Mark said: "Based on the guidance meeting with the FDA..."

So taking into consideration the FDA guidance this week, ANP are making plans for "global clinical development and commercialization".

Accumulate with ears pinned back